Renascience Inc. Logo

Renascience Inc.

Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.

4889 | T

Overview

Corporate Details

ISIN(s):
JP3981100005
LEI:
Country:
Japan
Address:
仙台市青葉区星陵町2−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Renascience Inc. is a research and development company engaged in the development and commercialization of pharmaceuticals and medical devices. The company focuses on creating innovative treatments derived from basic research to address various medical issues, including diseases associated with aging and hereditary conditions. Its R&D pipeline includes new drug candidates, such as antisense oligonucleotides, and advanced medical technology, such as a programmed medical device that utilizes artificial intelligence (AI) to support hemodialysis. Renascience actively forms strategic collaborations with pharmaceutical partners and academic institutions to advance its development projects and bring novel therapies to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:39
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-11-12 07:37
Interim Report
半期報告書-第27期(2025/04/01-2026/03/31)
Japanese 434.5 KB
2025-09-03 08:37
Regulatory News Service
確認書
Japanese 8.7 KB
2025-09-03 08:30
Regulatory News Service
訂正有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 1.7 MB
2025-06-27 08:35
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2025-06-24 08:36
Governance Information
内部統制報告書-第26期(2024/04/01-2025/03/31)
Japanese 23.2 KB
2025-06-24 08:35
Registration Form
確認書
Japanese 8.7 KB
2025-06-24 08:33
Registration Form
有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2024-11-14 07:37
Interim Report
確認書
Japanese 8.7 KB
2024-11-14 07:36
Interim Report
半期報告書-第26期(2024/04/01-2025/03/31)
Japanese 288.9 KB
2024-06-28 04:56
Post-Annual General Meeting Information
臨時報告書
Japanese 24.5 KB
2024-06-28 04:32
Governance Information
内部統制報告書-第25期(2023/04/01-2024/03/31)
Japanese 22.7 KB
2024-06-28 04:26
Registration Form
確認書
Japanese 8.7 KB
2024-06-28 04:24
Annual Report
有価証券報告書-第25期(2023/04/01-2024/03/31)
Japanese 3.5 MB
2024-05-27 10:10
Board/Management Information
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all Renascience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Renascience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Renascience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.